U.S. markets close in 1 hour 59 minutes
  • S&P 500

    3,853.46
    +1.61 (+0.04%)
     
  • Dow 30

    31,193.81
    +5.43 (+0.02%)
     
  • Nasdaq

    13,516.04
    +58.79 (+0.44%)
     
  • Russell 2000

    2,143.31
    -17.31 (-0.80%)
     
  • Crude Oil

    53.09
    -0.22 (-0.41%)
     
  • Gold

    1,866.10
    -0.40 (-0.02%)
     
  • Silver

    25.86
    +0.10 (+0.38%)
     
  • EUR/USD

    1.2160
    +0.0044 (+0.36%)
     
  • 10-Yr Bond

    1.1040
    +0.0140 (+1.28%)
     
  • GBP/USD

    1.3713
    +0.0057 (+0.42%)
     
  • USD/JPY

    103.5400
    -0.0300 (-0.03%)
     
  • BTC-USD

    31,761.45
    -3,190.23 (-9.13%)
     
  • CMC Crypto 200

    628.89
    -51.01 (-7.50%)
     
  • FTSE 100

    6,715.42
    -24.97 (-0.37%)
     
  • Nikkei 225

    28,756.86
    +233.60 (+0.82%)
     

Johnson & Johnson (JNJ) Stock Moves -0.42%: What You Should Know

Zacks Equity Research
·3 min read

Johnson & Johnson (JNJ) closed at $159.37 in the latest trading session, marking a -0.42% move from the prior day. This move was narrower than the S&P 500's daily loss of 0.66%. Elsewhere, the Dow lost 0.29%, while the tech-heavy Nasdaq lost 1.25%.

Heading into today, shares of the world's biggest maker of health care products had gained 5.12% over the past month, outpacing the Medical sector's gain of 1.53% and the S&P 500's gain of 3.42% in that time.

JNJ will be looking to display strength as it nears its next earnings release, which is expected to be January 26, 2021. On that day, JNJ is projected to report earnings of $1.82 per share, which would represent a year-over-year decline of 3.19%. Our most recent consensus estimate is calling for quarterly revenue of $21.82 billion, up 5.16% from the year-ago period.

Investors should also note any recent changes to analyst estimates for JNJ. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.11% lower. JNJ is currently sporting a Zacks Rank of #3 (Hold).

Investors should also note JNJ's current valuation metrics, including its Forward P/E ratio of 18.01. Its industry sports an average Forward P/E of 14.05, so we one might conclude that JNJ is trading at a premium comparatively.

It is also worth noting that JNJ currently has a PEG ratio of 3.1. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.04 at yesterday's closing price.

The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 97, which puts it in the top 39% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Johnson & Johnson (JNJ) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.